Influence of RFC1 c.80A & gt;G Polymorphism on Methotrexate-Mediated Toxicity and Therapeutic Efficacy in Rheumatoid Arthritis: A Meta-analysis
CONCLUSION AND RELEVANCE: RFC1 c.80 A>G is an important pharmacogenetic determinant of MTX therapy in RA. The RFC1 80A-allele robustly increased therapeutic efficacy and safety when folate was used along with MTX. Findings are relevant to decision-making in the clinical use of MTX as a treatment for RA patients harboring the RFC1 gene variant.PMID:33749319 | DOI:10.1177/10600280211002053
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Shaik Mohammad Naushad Salman A Alrokayan Fahad N Almajhdi Tajamul Hussain Source Type: research
More News: Arthritis | Drugs & Pharmacology | Genetics | Methotrexate | Rheumatoid Arthritis | Rheumatology | Study | Toxicology | Women